Clinical Trials Logo

Rabies clinical trials

View clinical trials related to Rabies.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06433440 Completed - Rabies Clinical Trials

Safety and Immunogenicity of Purified Verocell Rabies Vaccine PVRV Administered Intramuscularly and Intradermally

Start date: July 1, 2020
Phase: Phase 4
Study type: Interventional

Rabies is fatal disease but preventable with rabies vaccines and immunoglobulins, conventionally involves intramuscular (IM) administration of the vaccine. However, switching the intradermal (ID) route offers potential advantages in dosing, time and cost without compromising efficacy and safety. Therefore, this study aims to compare the safety and immunogenicity of a short-term three-doses intradermal regimen (3D-ID) with a conventional five-doses intramuscular regimen (5D-IM) of the purified Vero cell rabies vaccine (PVRV), administered via both intramuscular (IM) and intradermal (ID) routes as post-exposure prophylaxis (PEP).

NCT ID: NCT06177249 Completed - Rabies Human Clinical Trials

To Evaluate the Immunogenicity and Safety of Two Different Immunization Schedules of Rabies Vaccine (Vero Cell)

rabies
Start date: March 15, 2015
Phase: Phase 3
Study type: Interventional

To evaluate the safety and immunogenicity of lyophilized human rabies vaccine (Vero cell) developed by Hualan Biological in healthy people aged 9 to 65 years with two different immunization schedules.

NCT ID: NCT06078423 Completed - Clinical trials for Rabies Vaccine Adverse Reaction

A Clinical Trial of Freeze-dried Human Rabies Vaccine (MRC-5 Cells)

Start date: October 19, 2019
Phase: Phase 3
Study type: Interventional

This trial is a randomized, blind, similar vaccine controlled, single center, non-inferiority design phase III clinical trial, with a study population of 10 to 60 years old, conducted in two stages.Phase 1 and Phase 2

NCT ID: NCT05987384 Completed - Clinical trials for Rabies Vaccination Reaction

The Role of Fatty Acids in Vaccine Efficacy

Start date: May 3, 2023
Phase: N/A
Study type: Interventional

This study intends to use a randomized controlled trial design to vaccinate all participants against rabies and perform ARA interventions during vaccination to test the efficacy, safety, and intestinal flora of each group after immunization.

NCT ID: NCT05937113 Completed - Rabies Clinical Trials

Safety and Immunogenicity of the Inactivated Rabies Vaccine RABIVAX-S Administered Intramuscularly and Intradermally

Start date: June 13, 2020
Phase: Phase 4
Study type: Interventional

Randomized, open-label, prospective, before-and-after comparison study in the same group. Subjects suitable for the study will be randomly assigned at a ratio of 1:1 (block 4) to use the study vaccine by one of two routes of administration: Intramuscular or Intramuscular. Previously-unvaccinated subjects receive three injections of vaccine on day 0, 7 and 21-28. The aim of the study is to evaluate the safety and immunogenicity of the inactivated rabies vaccine RABIVAX-S administered intramuscularly and intradermally according to a 3-dose regimen in healthy volunteers.

NCT ID: NCT05702008 Completed - Rabies Clinical Trials

Social Media as an Information, Education and Communication Tool for Rabies Prevention: An Interventional Study

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

Background: Rabies is a fatal disease that can be avoided by treating animal bites promptly. Hence, post-exposure prophylaxis is critical. As a result, the National Rabies Control Program was approved under the 12th five-year plan in India. One of its strategies is to engage in Information, Education and Communication activities. Social media provides an opportunity for the quick and easy dissemination of research but is constrained by a lack of peer review and the risk of misinterpretation. The efficacy of a novel social media-based knowledge dissemination strategy for rabies prevention was tested in this study. Methods: An experimental study design was followed, wherein 144 preclinical medical students of Maulana Azad Medical College, Delhi, India were included in each control and test group. The test group was administered the intervention, which exposed the participants to health education material via social media across a span of 30 days. Participants' knowledge, attitude and practices were observed before and after the study duration.

NCT ID: NCT05684185 Completed - Clinical trials for Rabies Post-exposure Prophylaxis

Immunogenicity Assessment of Subjects Receiving Rabies Post-exposure Prophylaxis in Cambodia

Start date: July 15, 2020
Phase:
Study type: Observational

A rabies virus neutralizing antibody (RVNA) concentration ≥ 0.5 IU/ml at 14 days after immunization is considered a proxy for protection in vaccine efficacy studies. Abridged and dose-sparing vaccination regimens increase accessibility and reduce both direct and indirect costs, especially in resource-constrained countries where RABV prevalence is highest. Several efficacy studies evaluated safety and immunogenicity of abridged regimens in healthy adult volunteers using either four-site intradermal (ID) or intramuscular (IM) regimens, showing them to be safe and immunogenic. Researchers at the Institut Pasteur du Cambodge (IPC) have previously conducted a retrospective study on clinical outcome at ≥6 months in 3318 Cambodians who received intradermal Vero cell vaccine post-exposure prophylaxis after a bite by a rabid or sick-looking but untested dog in 2003-2014. Here, the investigators could show that there was no significant difference in survival among patients who received 3 versus 4 sessions of the Thai Red Cross (TRC) ID regimen. In a separate study, investigators measured antibody responses in order to evaluate the immunogenicity of the TRC regiment after 3 sessions versus 4 sessions. The investigators did not observe an increase in rabies virus seroneutralization titers 14 days after the fourth immunization compared to 14 days after the third immunization. These results contributed to changes endorsed by the WHO in its April 2018 guidelines. The "Institut Pasteur du Cambodge (IPC) regimen" of three PEP sessions of two-site ID 0.1 mL vaccine doses each at days 0, 3 and 7 is the first one-week PEP regimen to be recommended. In the current research project, the aim is to compare further different PEP vaccination strategies in a real life setting of individuals attending the rabies vaccination center at Institut Pasteur du Cambodge (IPC) in Phom Penh, Cambodia. The antibody kinetics and cellular immune responses in patients following either the one-week, 2-site ID regimen (IPC regimen) or the two-week IM regimen (4-dose regimen) as well as the participants' survival for both protocols after 6 months are evaluated.

NCT ID: NCT05549908 Completed - Rabies Human Clinical Trials

Vaccine Prevention of Rabies Adopts 4-shot Immunization Method

Start date: July 22, 2020
Phase: Phase 3
Study type: Interventional

A phase III clinical trial to evaluate the immunogenicity and safety of freeze-dried human rabies vaccine (Vero cell) developed by Changchun Zhuoyi Biological Co., Ltd. inoculated in a 4-dose procedure (2-1-1)

NCT ID: NCT05547815 Completed - Rabies Clinical Trials

Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine

Start date: November 11, 2019
Phase: Phase 4
Study type: Interventional

Evaluation of immune persistence after rabies vaccination in 150 people.

NCT ID: NCT05350735 Completed - Rabies Clinical Trials

Phone Text Message Reminders on Compliance With Human Rabies Post Exposure Prophylaxis Project

Start date: October 1, 2018
Phase: N/A
Study type: Interventional

Every year, rabies, a disease transmitted to humans by rabid dogs, is estimated to kill 59,000 people globally, mostly children 15 years and below in Africa and Asia. This is despite the availability of effective vaccines against rabies in humans, and in dogs. Following a dog bite, there are two critical steps required to prevent clinical disease and death: thorough wound washing with clean running water for at least 15 minutes; and immediate injection with anti-rabies vaccine on the day of being bitten followed by other four injections over the course of one month. Delay in seeking first dose of anti-rabies or failure to complete the recommended dosage may result in clinical rabies and death. The investigators proposed to assess the effect of short message system (SMS) phone text reminders sent to bite patients ahead of their scheduled visits on the adherence to scheduled anti-rabies doses among bite patients in rural eastern Kenya. The investigators enrolled bite patients presenting at Makueni County Referral Hospital between October 2018 and March 2019. Bite patients presenting to the facility between January and March 2019 received SMS reminder written in both English and local dialect a day before each dose of anti-rabies vaccine. These data were compared to those presenting to the health facility in the period prior (October to December 2018) before the introduction of the SMS reminder. This group received routine hospital cards as reminder of their next dose of anti-rabies vaccine injection. Each study participant was contacted after one month from the time of the bite and a phone interview completed to assess compliance and factors associated with completion of the five doses of anti-rabies vaccine.